Leukaemia (lymphocytic) - bendamustine (TA216)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
NICE recommends bendamustine as a possible treatment for some people with chronic lymphocytic leukaemia of Binet stage B or C
Who can have bendamustine?
You should be able to have bendamustine if:
- you have chronic lymphocytic leukaemia of Binet stage B or C that has not been treated before and
- you cannot have chemotherapy with a drug called fludarabine.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: blood and bone marrow cancers
This page was last updated: 27 February 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA216 Bendamustine fel triniaeth gyntaf ar gyfer lewcemia lymffosytig cronig: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.